nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—NME2—ovarian cancer	0.457	0.947	CbGaD
Lamivudine—SLC22A3—Melphalan—ovarian cancer	0.0891	0.281	CbGbCtD
Lamivudine—ABCG2—Topotecan—ovarian cancer	0.027	0.0852	CbGbCtD
Lamivudine—ABCB1—ovarian cancer	0.0255	0.0528	CbGaD
Lamivudine—ABCC1—Epirubicin—ovarian cancer	0.0202	0.0639	CbGbCtD
Lamivudine—ABCC1—Paclitaxel—ovarian cancer	0.02	0.063	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—ovarian cancer	0.0175	0.0553	CbGbCtD
Lamivudine—ABCC2—Paclitaxel—ovarian cancer	0.0148	0.0467	CbGbCtD
Lamivudine—ABCC1—Docetaxel—ovarian cancer	0.0144	0.0456	CbGbCtD
Lamivudine—ABCC2—Carboplatin—ovarian cancer	0.0139	0.0439	CbGbCtD
Lamivudine—ABCG2—Paclitaxel—ovarian cancer	0.0134	0.0422	CbGbCtD
Lamivudine—ABCG2—Carboplatin—ovarian cancer	0.0126	0.0397	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—ovarian cancer	0.0108	0.034	CbGbCtD
Lamivudine—ABCC2—Docetaxel—ovarian cancer	0.0107	0.0337	CbGbCtD
Lamivudine—ABCB1—Topotecan—ovarian cancer	0.00973	0.0307	CbGbCtD
Lamivudine—ABCG2—Docetaxel—ovarian cancer	0.00966	0.0305	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—ovarian cancer	0.00796	0.0251	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—ovarian cancer	0.0072	0.0227	CbGbCtD
Lamivudine—ABCB1—Vinorelbine—ovarian cancer	0.00685	0.0216	CbGbCtD
Lamivudine—ABCB1—Paclitaxel—ovarian cancer	0.00482	0.0152	CbGbCtD
Lamivudine—ABCB1—Docetaxel—ovarian cancer	0.00348	0.011	CbGbCtD
Lamivudine—ABCB1—Doxorubicin—ovarian cancer	0.0026	0.0082	CbGbCtD
Lamivudine—PCYT2—gonad—ovarian cancer	0.0017	0.0326	CbGeAlD
Lamivudine—PCYT2—female reproductive system—ovarian cancer	0.00152	0.0291	CbGeAlD
Lamivudine—PGK1—gonad—ovarian cancer	0.00146	0.028	CbGeAlD
Lamivudine—PGK1—uterus—ovarian cancer	0.00145	0.0278	CbGeAlD
Lamivudine—PGK1—female reproductive system—ovarian cancer	0.0013	0.025	CbGeAlD
Lamivudine—PCYT2—testis—ovarian cancer	0.00123	0.0235	CbGeAlD
Lamivudine—NT5C—uterus—ovarian cancer	0.00123	0.0235	CbGeAlD
Lamivudine—NME1-NME2—female reproductive system—ovarian cancer	0.00119	0.0228	CbGeAlD
Lamivudine—PCYT1A—gonad—ovarian cancer	0.00116	0.0222	CbGeAlD
Lamivudine—NT5C—female reproductive system—ovarian cancer	0.0011	0.0211	CbGeAlD
Lamivudine—NME2—embryo—ovarian cancer	0.00107	0.0206	CbGeAlD
Lamivudine—PGK1—testis—ovarian cancer	0.00105	0.0202	CbGeAlD
Lamivudine—PCYT1A—female reproductive system—ovarian cancer	0.00103	0.0198	CbGeAlD
Lamivudine—NT5C—female gonad—ovarian cancer	0.001	0.0192	CbGeAlD
Lamivudine—NT5C—vagina—ovarian cancer	0.000996	0.0191	CbGeAlD
Lamivudine—CMPK1—uterine cervix—ovarian cancer	0.000889	0.017	CbGeAlD
Lamivudine—NT5C—testis—ovarian cancer	0.000889	0.017	CbGeAlD
Lamivudine—NME2—epithelium—ovarian cancer	0.000876	0.0168	CbGeAlD
Lamivudine—CMPK1—decidua—ovarian cancer	0.000847	0.0162	CbGeAlD
Lamivudine—PCYT1A—testis—ovarian cancer	0.000834	0.016	CbGeAlD
Lamivudine—NME1—uterus—ovarian cancer	0.000769	0.0147	CbGeAlD
Lamivudine—CMPK1—gonad—ovarian cancer	0.000746	0.0143	CbGeAlD
Lamivudine—Gemcitabine—TYMS—ovarian cancer	0.000743	0.798	CrCbGaD
Lamivudine—CMPK1—uterus—ovarian cancer	0.000741	0.0142	CbGeAlD
Lamivudine—NME1-NME2—lymph node—ovarian cancer	0.000695	0.0133	CbGeAlD
Lamivudine—NME1—female reproductive system—ovarian cancer	0.000691	0.0132	CbGeAlD
Lamivudine—CMPK1—female reproductive system—ovarian cancer	0.000666	0.0128	CbGeAlD
Lamivudine—NME1—bone marrow—ovarian cancer	0.000653	0.0125	CbGeAlD
Lamivudine—NME2—female reproductive system—ovarian cancer	0.000651	0.0125	CbGeAlD
Lamivudine—NT5C—lymph node—ovarian cancer	0.000644	0.0124	CbGeAlD
Lamivudine—NME1—female gonad—ovarian cancer	0.000629	0.0121	CbGeAlD
Lamivudine—CMPK1—bone marrow—ovarian cancer	0.000629	0.0121	CbGeAlD
Lamivudine—CMPK1—female gonad—ovarian cancer	0.000606	0.0116	CbGeAlD
Lamivudine—CMPK1—vagina—ovarian cancer	0.000602	0.0115	CbGeAlD
Lamivudine—NME2—female gonad—ovarian cancer	0.000592	0.0114	CbGeAlD
Lamivudine—DCK—myometrium—ovarian cancer	0.000569	0.0109	CbGeAlD
Lamivudine—NME1—testis—ovarian cancer	0.000558	0.0107	CbGeAlD
Lamivudine—DCK—embryo—ovarian cancer	0.000547	0.0105	CbGeAlD
Lamivudine—CMPK1—testis—ovarian cancer	0.000538	0.0103	CbGeAlD
Lamivudine—NME2—testis—ovarian cancer	0.000525	0.0101	CbGeAlD
Lamivudine—SLC22A3—myometrium—ovarian cancer	0.000464	0.00889	CbGeAlD
Lamivudine—DCK—Doxorubicin—Epirubicin—ovarian cancer	0.000459	0.519	CbGdCrCtD
Lamivudine—SLC22A3—embryo—ovarian cancer	0.000446	0.00855	CbGeAlD
Lamivudine—DCK—uterine cervix—ovarian cancer	0.000443	0.00849	CbGeAlD
Lamivudine—DCK—Epirubicin—Doxorubicin—ovarian cancer	0.000425	0.481	CbGdCrCtD
Lamivudine—DCK—decidua—ovarian cancer	0.000422	0.00808	CbGeAlD
Lamivudine—NME1—lymph node—ovarian cancer	0.000404	0.00775	CbGeAlD
Lamivudine—ABCC3—decidua—ovarian cancer	0.000404	0.00774	CbGeAlD
Lamivudine—DCK—endometrium—ovarian cancer	0.0004	0.00767	CbGeAlD
Lamivudine—CMPK1—lymph node—ovarian cancer	0.00039	0.00747	CbGeAlD
Lamivudine—ABCC1—myometrium—ovarian cancer	0.000383	0.00735	CbGeAlD
Lamivudine—NME2—lymph node—ovarian cancer	0.000381	0.0073	CbGeAlD
Lamivudine—DCK—gonad—ovarian cancer	0.000371	0.00712	CbGeAlD
Lamivudine—DCK—uterus—ovarian cancer	0.000369	0.00707	CbGeAlD
Lamivudine—SLC22A3—uterine cervix—ovarian cancer	0.000361	0.00692	CbGeAlD
Lamivudine—DCK—female reproductive system—ovarian cancer	0.000332	0.00636	CbGeAlD
Lamivudine—SLC22A3—endometrium—ovarian cancer	0.000326	0.00626	CbGeAlD
Lamivudine—ABCC3—female reproductive system—ovarian cancer	0.000318	0.00609	CbGeAlD
Lamivudine—ABCG2—myometrium—ovarian cancer	0.000317	0.00608	CbGeAlD
Lamivudine—DCK—bone marrow—ovarian cancer	0.000313	0.006	CbGeAlD
Lamivudine—SLC22A3—gonad—ovarian cancer	0.000303	0.0058	CbGeAlD
Lamivudine—DCK—female gonad—ovarian cancer	0.000302	0.00578	CbGeAlD
Lamivudine—DCK—vagina—ovarian cancer	0.0003	0.00575	CbGeAlD
Lamivudine—ABCC1—uterine cervix—ovarian cancer	0.000298	0.00572	CbGeAlD
Lamivudine—ABCC4—uterus—ovarian cancer	0.000292	0.00559	CbGeAlD
Lamivudine—ABCC3—female gonad—ovarian cancer	0.000289	0.00554	CbGeAlD
Lamivudine—ABCC1—decidua—ovarian cancer	0.000284	0.00545	CbGeAlD
Lamivudine—SLC22A3—female reproductive system—ovarian cancer	0.00027	0.00518	CbGeAlD
Lamivudine—ABCC1—endometrium—ovarian cancer	0.00027	0.00517	CbGeAlD
Lamivudine—DCK—testis—ovarian cancer	0.000268	0.00513	CbGeAlD
Lamivudine—ABCC4—female reproductive system—ovarian cancer	0.000262	0.00502	CbGeAlD
Lamivudine—ABCC3—testis—ovarian cancer	0.000256	0.00491	CbGeAlD
Lamivudine—SLC22A1—vagina—ovarian cancer	0.000256	0.0049	CbGeAlD
Lamivudine—ABCC2—female reproductive system—ovarian cancer	0.000254	0.00486	CbGeAlD
Lamivudine—ABCC1—uterus—ovarian cancer	0.000249	0.00477	CbGeAlD
Lamivudine—ABCC4—bone marrow—ovarian cancer	0.000247	0.00474	CbGeAlD
Lamivudine—ABCG2—uterine cervix—ovarian cancer	0.000247	0.00473	CbGeAlD
Lamivudine—SLC22A3—female gonad—ovarian cancer	0.000246	0.00472	CbGeAlD
Lamivudine—SLC22A3—vagina—ovarian cancer	0.000244	0.00469	CbGeAlD
Lamivudine—ABCC4—female gonad—ovarian cancer	0.000239	0.00457	CbGeAlD
Lamivudine—ABCG2—decidua—ovarian cancer	0.000235	0.00451	CbGeAlD
Lamivudine—ABCG2—endometrium—ovarian cancer	0.000223	0.00428	CbGeAlD
Lamivudine—SLC22A3—testis—ovarian cancer	0.000218	0.00418	CbGeAlD
Lamivudine—ABCC4—testis—ovarian cancer	0.000212	0.00405	CbGeAlD
Lamivudine—ABCG2—uterus—ovarian cancer	0.000206	0.00395	CbGeAlD
Lamivudine—ABCC2—testis—ovarian cancer	0.000205	0.00392	CbGeAlD
Lamivudine—ABCC1—female gonad—ovarian cancer	0.000203	0.0039	CbGeAlD
Lamivudine—ABCC1—vagina—ovarian cancer	0.000202	0.00387	CbGeAlD
Lamivudine—DCK—lymph node—ovarian cancer	0.000194	0.00372	CbGeAlD
Lamivudine—Gemcitabine—ABCB1—ovarian cancer	0.000188	0.202	CrCbGaD
Lamivudine—ABCC3—lymph node—ovarian cancer	0.000186	0.00356	CbGeAlD
Lamivudine—ABCC1—testis—ovarian cancer	0.00018	0.00346	CbGeAlD
Lamivudine—ABCG2—bone marrow—ovarian cancer	0.000175	0.00335	CbGeAlD
Lamivudine—ABCG2—female gonad—ovarian cancer	0.000168	0.00323	CbGeAlD
Lamivudine—ABCG2—vagina—ovarian cancer	0.000167	0.00321	CbGeAlD
Lamivudine—SLC22A3—lymph node—ovarian cancer	0.000158	0.00303	CbGeAlD
Lamivudine—ABCB1—myometrium—ovarian cancer	0.000156	0.003	CbGeAlD
Lamivudine—ABCC4—lymph node—ovarian cancer	0.000153	0.00294	CbGeAlD
Lamivudine—ABCB1—embryo—ovarian cancer	0.000151	0.00289	CbGeAlD
Lamivudine—ABCG2—testis—ovarian cancer	0.000149	0.00286	CbGeAlD
Lamivudine—ABCC2—lymph node—ovarian cancer	0.000148	0.00285	CbGeAlD
Lamivudine—ABCC1—lymph node—ovarian cancer	0.000131	0.00251	CbGeAlD
Lamivudine—ABCB1—epithelium—ovarian cancer	0.000123	0.00235	CbGeAlD
Lamivudine—ABCB1—uterine cervix—ovarian cancer	0.000122	0.00233	CbGeAlD
Lamivudine—ABCB1—decidua—ovarian cancer	0.000116	0.00222	CbGeAlD
Lamivudine—ABCB1—endometrium—ovarian cancer	0.00011	0.00211	CbGeAlD
Lamivudine—ABCG2—lymph node—ovarian cancer	0.000108	0.00207	CbGeAlD
Lamivudine—ABCB1—gonad—ovarian cancer	0.000102	0.00196	CbGeAlD
Lamivudine—ABCB1—uterus—ovarian cancer	0.000101	0.00195	CbGeAlD
Lamivudine—ABCB1—female reproductive system—ovarian cancer	9.12e-05	0.00175	CbGeAlD
Lamivudine—ABCB1—bone marrow—ovarian cancer	8.61e-05	0.00165	CbGeAlD
Lamivudine—ABCB1—female gonad—ovarian cancer	8.3e-05	0.00159	CbGeAlD
Lamivudine—ABCB1—vagina—ovarian cancer	8.25e-05	0.00158	CbGeAlD
Lamivudine—ABCB1—testis—ovarian cancer	7.36e-05	0.00141	CbGeAlD
Lamivudine—Rash—Vinorelbine—ovarian cancer	6.03e-05	0.00067	CcSEcCtD
Lamivudine—Dermatitis—Vinorelbine—ovarian cancer	6.02e-05	0.00067	CcSEcCtD
Lamivudine—Abdominal distension—Doxorubicin—ovarian cancer	6.02e-05	0.00067	CcSEcCtD
Lamivudine—Hypotension—Paclitaxel—ovarian cancer	6.01e-05	0.000668	CcSEcCtD
Lamivudine—Headache—Vinorelbine—ovarian cancer	5.99e-05	0.000666	CcSEcCtD
Lamivudine—Syncope—Docetaxel—ovarian cancer	5.99e-05	0.000666	CcSEcCtD
Lamivudine—Influenza—Doxorubicin—ovarian cancer	5.98e-05	0.000665	CcSEcCtD
Lamivudine—Dysphagia—Doxorubicin—ovarian cancer	5.98e-05	0.000665	CcSEcCtD
Lamivudine—Leukopenia—Docetaxel—ovarian cancer	5.98e-05	0.000665	CcSEcCtD
Lamivudine—Pollakiuria—Epirubicin—ovarian cancer	5.97e-05	0.000664	CcSEcCtD
Lamivudine—Loss of consciousness—Docetaxel—ovarian cancer	5.87e-05	0.000653	CcSEcCtD
Lamivudine—Pancreatitis—Doxorubicin—ovarian cancer	5.86e-05	0.000652	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	5.86e-05	0.000651	CcSEcCtD
Lamivudine—Hyperglycaemia—Epirubicin—ovarian cancer	5.83e-05	0.000648	CcSEcCtD
Lamivudine—Cough—Docetaxel—ovarian cancer	5.83e-05	0.000648	CcSEcCtD
Lamivudine—Insomnia—Paclitaxel—ovarian cancer	5.82e-05	0.000647	CcSEcCtD
Lamivudine—Convulsion—Docetaxel—ovarian cancer	5.79e-05	0.000643	CcSEcCtD
Lamivudine—Paraesthesia—Paclitaxel—ovarian cancer	5.77e-05	0.000642	CcSEcCtD
Lamivudine—Bronchitis—Doxorubicin—ovarian cancer	5.75e-05	0.00064	CcSEcCtD
Lamivudine—Dyspnoea—Paclitaxel—ovarian cancer	5.73e-05	0.000637	CcSEcCtD
Lamivudine—Somnolence—Paclitaxel—ovarian cancer	5.72e-05	0.000636	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	5.71e-05	0.000635	CcSEcCtD
Lamivudine—Chest pain—Docetaxel—ovarian cancer	5.69e-05	0.000632	CcSEcCtD
Lamivudine—Arthralgia—Docetaxel—ovarian cancer	5.69e-05	0.000632	CcSEcCtD
Lamivudine—Myalgia—Docetaxel—ovarian cancer	5.69e-05	0.000632	CcSEcCtD
Lamivudine—Pancytopenia—Doxorubicin—ovarian cancer	5.68e-05	0.000632	CcSEcCtD
Lamivudine—Nausea—Vinorelbine—ovarian cancer	5.68e-05	0.000631	CcSEcCtD
Lamivudine—Renal failure—Epirubicin—ovarian cancer	5.67e-05	0.00063	CcSEcCtD
Lamivudine—Dyspepsia—Paclitaxel—ovarian cancer	5.66e-05	0.000629	CcSEcCtD
Lamivudine—Neuropathy peripheral—Epirubicin—ovarian cancer	5.65e-05	0.000628	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	5.65e-05	0.000628	CcSEcCtD
Lamivudine—Stomatitis—Epirubicin—ovarian cancer	5.62e-05	0.000625	CcSEcCtD
Lamivudine—Jaundice—Epirubicin—ovarian cancer	5.62e-05	0.000625	CcSEcCtD
Lamivudine—Neutropenia—Doxorubicin—ovarian cancer	5.59e-05	0.000622	CcSEcCtD
Lamivudine—Dysuria—Doxorubicin—ovarian cancer	5.59e-05	0.000622	CcSEcCtD
Lamivudine—Decreased appetite—Paclitaxel—ovarian cancer	5.59e-05	0.000622	CcSEcCtD
Lamivudine—Dry mouth—Docetaxel—ovarian cancer	5.56e-05	0.000618	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	5.55e-05	0.000617	CcSEcCtD
Lamivudine—Fatigue—Paclitaxel—ovarian cancer	5.54e-05	0.000616	CcSEcCtD
Lamivudine—Sweating—Epirubicin—ovarian cancer	5.53e-05	0.000614	CcSEcCtD
Lamivudine—Pollakiuria—Doxorubicin—ovarian cancer	5.53e-05	0.000614	CcSEcCtD
Lamivudine—Constipation—Paclitaxel—ovarian cancer	5.5e-05	0.000611	CcSEcCtD
Lamivudine—Pain—Paclitaxel—ovarian cancer	5.5e-05	0.000611	CcSEcCtD
Lamivudine—Confusional state—Docetaxel—ovarian cancer	5.5e-05	0.000611	CcSEcCtD
Lamivudine—Hepatobiliary disease—Epirubicin—ovarian cancer	5.45e-05	0.000606	CcSEcCtD
Lamivudine—Oedema—Docetaxel—ovarian cancer	5.45e-05	0.000606	CcSEcCtD
Lamivudine—Anaphylactic shock—Docetaxel—ovarian cancer	5.45e-05	0.000606	CcSEcCtD
Lamivudine—Epistaxis—Epirubicin—ovarian cancer	5.44e-05	0.000605	CcSEcCtD
Lamivudine—Infection—Docetaxel—ovarian cancer	5.41e-05	0.000602	CcSEcCtD
Lamivudine—Sinusitis—Epirubicin—ovarian cancer	5.41e-05	0.000601	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—ovarian cancer	5.4e-05	0.0006	CcSEcCtD
Lamivudine—Agranulocytosis—Epirubicin—ovarian cancer	5.38e-05	0.000598	CcSEcCtD
Lamivudine—Shock—Docetaxel—ovarian cancer	5.36e-05	0.000596	CcSEcCtD
Lamivudine—Nervous system disorder—Docetaxel—ovarian cancer	5.35e-05	0.000594	CcSEcCtD
Lamivudine—ABCB1—lymph node—ovarian cancer	5.34e-05	0.00102	CbGeAlD
Lamivudine—Thrombocytopenia—Docetaxel—ovarian cancer	5.34e-05	0.000593	CcSEcCtD
Lamivudine—Feeling abnormal—Paclitaxel—ovarian cancer	5.3e-05	0.000589	CcSEcCtD
Lamivudine—Skin disorder—Docetaxel—ovarian cancer	5.29e-05	0.000589	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	5.29e-05	0.000588	CcSEcCtD
Lamivudine—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.26e-05	0.000585	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—ovarian cancer	5.24e-05	0.000583	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—ovarian cancer	5.23e-05	0.000581	CcSEcCtD
Lamivudine—Stomatitis—Doxorubicin—ovarian cancer	5.2e-05	0.000578	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—ovarian cancer	5.2e-05	0.000578	CcSEcCtD
Lamivudine—Anorexia—Docetaxel—ovarian cancer	5.2e-05	0.000578	CcSEcCtD
Lamivudine—Rhinitis—Epirubicin—ovarian cancer	5.19e-05	0.000577	CcSEcCtD
Lamivudine—Hepatitis—Epirubicin—ovarian cancer	5.17e-05	0.000575	CcSEcCtD
Lamivudine—Hypoaesthesia—Epirubicin—ovarian cancer	5.15e-05	0.000572	CcSEcCtD
Lamivudine—Pharyngitis—Epirubicin—ovarian cancer	5.14e-05	0.000571	CcSEcCtD
Lamivudine—Sweating—Doxorubicin—ovarian cancer	5.11e-05	0.000569	CcSEcCtD
Lamivudine—Urticaria—Paclitaxel—ovarian cancer	5.11e-05	0.000568	CcSEcCtD
Lamivudine—Hypotension—Docetaxel—ovarian cancer	5.09e-05	0.000566	CcSEcCtD
Lamivudine—Connective tissue disorder—Epirubicin—ovarian cancer	5.08e-05	0.000565	CcSEcCtD
Lamivudine—Abdominal pain—Paclitaxel—ovarian cancer	5.08e-05	0.000565	CcSEcCtD
Lamivudine—Body temperature increased—Paclitaxel—ovarian cancer	5.08e-05	0.000565	CcSEcCtD
Lamivudine—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.04e-05	0.000561	CcSEcCtD
Lamivudine—Epistaxis—Doxorubicin—ovarian cancer	5.03e-05	0.000559	CcSEcCtD
Lamivudine—Sinusitis—Doxorubicin—ovarian cancer	5e-05	0.000556	CcSEcCtD
Lamivudine—Agranulocytosis—Doxorubicin—ovarian cancer	4.98e-05	0.000553	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	4.97e-05	0.000552	CcSEcCtD
Lamivudine—Insomnia—Docetaxel—ovarian cancer	4.93e-05	0.000548	CcSEcCtD
Lamivudine—Paraesthesia—Docetaxel—ovarian cancer	4.89e-05	0.000544	CcSEcCtD
Lamivudine—Erythema multiforme—Epirubicin—ovarian cancer	4.89e-05	0.000544	CcSEcCtD
Lamivudine—Dyspnoea—Docetaxel—ovarian cancer	4.86e-05	0.00054	CcSEcCtD
Lamivudine—Somnolence—Docetaxel—ovarian cancer	4.85e-05	0.000539	CcSEcCtD
Lamivudine—Rhinitis—Doxorubicin—ovarian cancer	4.8e-05	0.000534	CcSEcCtD
Lamivudine—Dyspepsia—Docetaxel—ovarian cancer	4.8e-05	0.000533	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—ovarian cancer	4.79e-05	0.000532	CcSEcCtD
Lamivudine—Hypoaesthesia—Doxorubicin—ovarian cancer	4.76e-05	0.00053	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—ovarian cancer	4.75e-05	0.000528	CcSEcCtD
Lamivudine—Decreased appetite—Docetaxel—ovarian cancer	4.74e-05	0.000527	CcSEcCtD
Lamivudine—Hypersensitivity—Paclitaxel—ovarian cancer	4.74e-05	0.000527	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Docetaxel—ovarian cancer	4.71e-05	0.000523	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—ovarian cancer	4.7e-05	0.000523	CcSEcCtD
Lamivudine—Fatigue—Docetaxel—ovarian cancer	4.7e-05	0.000522	CcSEcCtD
Lamivudine—Immune system disorder—Epirubicin—ovarian cancer	4.67e-05	0.00052	CcSEcCtD
Lamivudine—Mediastinal disorder—Epirubicin—ovarian cancer	4.66e-05	0.000519	CcSEcCtD
Lamivudine—Constipation—Docetaxel—ovarian cancer	4.66e-05	0.000518	CcSEcCtD
Lamivudine—Pain—Docetaxel—ovarian cancer	4.66e-05	0.000518	CcSEcCtD
Lamivudine—Chills—Epirubicin—ovarian cancer	4.64e-05	0.000516	CcSEcCtD
Lamivudine—Asthenia—Paclitaxel—ovarian cancer	4.61e-05	0.000513	CcSEcCtD
Lamivudine—Alopecia—Epirubicin—ovarian cancer	4.57e-05	0.000508	CcSEcCtD
Lamivudine—Pruritus—Paclitaxel—ovarian cancer	4.55e-05	0.000506	CcSEcCtD
Lamivudine—Erythema multiforme—Doxorubicin—ovarian cancer	4.53e-05	0.000503	CcSEcCtD
Lamivudine—Malnutrition—Epirubicin—ovarian cancer	4.5e-05	0.000501	CcSEcCtD
Lamivudine—Erythema—Epirubicin—ovarian cancer	4.5e-05	0.000501	CcSEcCtD
Lamivudine—Feeling abnormal—Docetaxel—ovarian cancer	4.49e-05	0.000499	CcSEcCtD
Lamivudine—Gastrointestinal pain—Docetaxel—ovarian cancer	4.46e-05	0.000496	CcSEcCtD
Lamivudine—Flatulence—Epirubicin—ovarian cancer	4.44e-05	0.000494	CcSEcCtD
Lamivudine—Tension—Epirubicin—ovarian cancer	4.42e-05	0.000491	CcSEcCtD
Lamivudine—Dysgeusia—Epirubicin—ovarian cancer	4.41e-05	0.00049	CcSEcCtD
Lamivudine—Diarrhoea—Paclitaxel—ovarian cancer	4.4e-05	0.000489	CcSEcCtD
Lamivudine—Nervousness—Epirubicin—ovarian cancer	4.37e-05	0.000486	CcSEcCtD
Lamivudine—Back pain—Epirubicin—ovarian cancer	4.36e-05	0.000484	CcSEcCtD
Lamivudine—Muscle spasms—Epirubicin—ovarian cancer	4.33e-05	0.000482	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—ovarian cancer	4.32e-05	0.000481	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—ovarian cancer	4.31e-05	0.00048	CcSEcCtD
Lamivudine—Abdominal pain—Docetaxel—ovarian cancer	4.31e-05	0.000479	CcSEcCtD
Lamivudine—Body temperature increased—Docetaxel—ovarian cancer	4.31e-05	0.000479	CcSEcCtD
Lamivudine—Chills—Doxorubicin—ovarian cancer	4.3e-05	0.000478	CcSEcCtD
Lamivudine—Dizziness—Paclitaxel—ovarian cancer	4.25e-05	0.000473	CcSEcCtD
Lamivudine—Alopecia—Doxorubicin—ovarian cancer	4.23e-05	0.00047	CcSEcCtD
Lamivudine—Ill-defined disorder—Epirubicin—ovarian cancer	4.18e-05	0.000465	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—ovarian cancer	4.17e-05	0.000463	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—ovarian cancer	4.17e-05	0.000463	CcSEcCtD
Lamivudine—Anaemia—Epirubicin—ovarian cancer	4.16e-05	0.000463	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—ovarian cancer	4.11e-05	0.000457	CcSEcCtD
Lamivudine—Tension—Doxorubicin—ovarian cancer	4.09e-05	0.000455	CcSEcCtD
Lamivudine—Vomiting—Paclitaxel—ovarian cancer	4.09e-05	0.000455	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—ovarian cancer	4.08e-05	0.000454	CcSEcCtD
Lamivudine—Malaise—Epirubicin—ovarian cancer	4.06e-05	0.000452	CcSEcCtD
Lamivudine—Rash—Paclitaxel—ovarian cancer	4.05e-05	0.000451	CcSEcCtD
Lamivudine—Dermatitis—Paclitaxel—ovarian cancer	4.05e-05	0.00045	CcSEcCtD
Lamivudine—Nervousness—Doxorubicin—ovarian cancer	4.05e-05	0.00045	CcSEcCtD
Lamivudine—Vertigo—Epirubicin—ovarian cancer	4.05e-05	0.00045	CcSEcCtD
Lamivudine—Syncope—Epirubicin—ovarian cancer	4.04e-05	0.000449	CcSEcCtD
Lamivudine—Leukopenia—Epirubicin—ovarian cancer	4.03e-05	0.000448	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—ovarian cancer	4.03e-05	0.000448	CcSEcCtD
Lamivudine—Headache—Paclitaxel—ovarian cancer	4.03e-05	0.000448	CcSEcCtD
Lamivudine—Hypersensitivity—Docetaxel—ovarian cancer	4.02e-05	0.000447	CcSEcCtD
Lamivudine—Muscle spasms—Doxorubicin—ovarian cancer	4.01e-05	0.000446	CcSEcCtD
Lamivudine—Loss of consciousness—Epirubicin—ovarian cancer	3.96e-05	0.00044	CcSEcCtD
Lamivudine—Cough—Epirubicin—ovarian cancer	3.93e-05	0.000437	CcSEcCtD
Lamivudine—Asthenia—Docetaxel—ovarian cancer	3.91e-05	0.000435	CcSEcCtD
Lamivudine—Convulsion—Epirubicin—ovarian cancer	3.9e-05	0.000434	CcSEcCtD
Lamivudine—Ill-defined disorder—Doxorubicin—ovarian cancer	3.87e-05	0.00043	CcSEcCtD
Lamivudine—Pruritus—Docetaxel—ovarian cancer	3.86e-05	0.000429	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—ovarian cancer	3.85e-05	0.000428	CcSEcCtD
Lamivudine—Chest pain—Epirubicin—ovarian cancer	3.83e-05	0.000426	CcSEcCtD
Lamivudine—Myalgia—Epirubicin—ovarian cancer	3.83e-05	0.000426	CcSEcCtD
Lamivudine—Arthralgia—Epirubicin—ovarian cancer	3.83e-05	0.000426	CcSEcCtD
Lamivudine—Anxiety—Epirubicin—ovarian cancer	3.82e-05	0.000425	CcSEcCtD
Lamivudine—Nausea—Paclitaxel—ovarian cancer	3.82e-05	0.000425	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.81e-05	0.000423	CcSEcCtD
Lamivudine—Discomfort—Epirubicin—ovarian cancer	3.79e-05	0.000421	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—ovarian cancer	3.76e-05	0.000418	CcSEcCtD
Lamivudine—Dry mouth—Epirubicin—ovarian cancer	3.75e-05	0.000417	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—ovarian cancer	3.74e-05	0.000416	CcSEcCtD
Lamivudine—Syncope—Doxorubicin—ovarian cancer	3.74e-05	0.000416	CcSEcCtD
Lamivudine—Leukopenia—Doxorubicin—ovarian cancer	3.73e-05	0.000415	CcSEcCtD
Lamivudine—Diarrhoea—Docetaxel—ovarian cancer	3.73e-05	0.000415	CcSEcCtD
Lamivudine—Confusional state—Epirubicin—ovarian cancer	3.71e-05	0.000412	CcSEcCtD
Lamivudine—Anaphylactic shock—Epirubicin—ovarian cancer	3.68e-05	0.000409	CcSEcCtD
Lamivudine—Oedema—Epirubicin—ovarian cancer	3.68e-05	0.000409	CcSEcCtD
Lamivudine—Loss of consciousness—Doxorubicin—ovarian cancer	3.66e-05	0.000407	CcSEcCtD
Lamivudine—Infection—Epirubicin—ovarian cancer	3.65e-05	0.000406	CcSEcCtD
Lamivudine—Cough—Doxorubicin—ovarian cancer	3.64e-05	0.000404	CcSEcCtD
Lamivudine—Shock—Epirubicin—ovarian cancer	3.62e-05	0.000402	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—ovarian cancer	3.61e-05	0.000402	CcSEcCtD
Lamivudine—Nervous system disorder—Epirubicin—ovarian cancer	3.61e-05	0.000401	CcSEcCtD
Lamivudine—Dizziness—Docetaxel—ovarian cancer	3.6e-05	0.000401	CcSEcCtD
Lamivudine—Thrombocytopenia—Epirubicin—ovarian cancer	3.6e-05	0.0004	CcSEcCtD
Lamivudine—Skin disorder—Epirubicin—ovarian cancer	3.57e-05	0.000397	CcSEcCtD
Lamivudine—Hyperhidrosis—Epirubicin—ovarian cancer	3.55e-05	0.000395	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—ovarian cancer	3.55e-05	0.000395	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—ovarian cancer	3.55e-05	0.000395	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—ovarian cancer	3.55e-05	0.000395	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—ovarian cancer	3.54e-05	0.000393	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.52e-05	0.000392	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—ovarian cancer	3.51e-05	0.00039	CcSEcCtD
Lamivudine—Anorexia—Epirubicin—ovarian cancer	3.5e-05	0.00039	CcSEcCtD
Lamivudine—Dry mouth—Doxorubicin—ovarian cancer	3.47e-05	0.000386	CcSEcCtD
Lamivudine—Vomiting—Docetaxel—ovarian cancer	3.47e-05	0.000385	CcSEcCtD
Lamivudine—Rash—Docetaxel—ovarian cancer	3.44e-05	0.000382	CcSEcCtD
Lamivudine—Hypotension—Epirubicin—ovarian cancer	3.44e-05	0.000382	CcSEcCtD
Lamivudine—Dermatitis—Docetaxel—ovarian cancer	3.43e-05	0.000382	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—ovarian cancer	3.43e-05	0.000381	CcSEcCtD
Lamivudine—Headache—Docetaxel—ovarian cancer	3.41e-05	0.00038	CcSEcCtD
Lamivudine—Oedema—Doxorubicin—ovarian cancer	3.4e-05	0.000378	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—ovarian cancer	3.4e-05	0.000378	CcSEcCtD
Lamivudine—Infection—Doxorubicin—ovarian cancer	3.38e-05	0.000376	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.35e-05	0.000372	CcSEcCtD
Lamivudine—Shock—Doxorubicin—ovarian cancer	3.35e-05	0.000372	CcSEcCtD
Lamivudine—Nervous system disorder—Doxorubicin—ovarian cancer	3.34e-05	0.000371	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—ovarian cancer	3.33e-05	0.00037	CcSEcCtD
Lamivudine—Insomnia—Epirubicin—ovarian cancer	3.33e-05	0.00037	CcSEcCtD
Lamivudine—Skin disorder—Doxorubicin—ovarian cancer	3.3e-05	0.000367	CcSEcCtD
Lamivudine—Paraesthesia—Epirubicin—ovarian cancer	3.3e-05	0.000367	CcSEcCtD
Lamivudine—Hyperhidrosis—Doxorubicin—ovarian cancer	3.29e-05	0.000366	CcSEcCtD
Lamivudine—Dyspnoea—Epirubicin—ovarian cancer	3.28e-05	0.000364	CcSEcCtD
Lamivudine—Somnolence—Epirubicin—ovarian cancer	3.27e-05	0.000363	CcSEcCtD
Lamivudine—Anorexia—Doxorubicin—ovarian cancer	3.24e-05	0.000361	CcSEcCtD
Lamivudine—Nausea—Docetaxel—ovarian cancer	3.24e-05	0.00036	CcSEcCtD
Lamivudine—Dyspepsia—Epirubicin—ovarian cancer	3.24e-05	0.00036	CcSEcCtD
Lamivudine—Decreased appetite—Epirubicin—ovarian cancer	3.2e-05	0.000355	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—ovarian cancer	3.18e-05	0.000353	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.17e-05	0.000353	CcSEcCtD
Lamivudine—Fatigue—Epirubicin—ovarian cancer	3.17e-05	0.000352	CcSEcCtD
Lamivudine—Pain—Epirubicin—ovarian cancer	3.14e-05	0.00035	CcSEcCtD
Lamivudine—Constipation—Epirubicin—ovarian cancer	3.14e-05	0.00035	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.1e-05	0.000345	CcSEcCtD
Lamivudine—Insomnia—Doxorubicin—ovarian cancer	3.08e-05	0.000342	CcSEcCtD
Lamivudine—Paraesthesia—Doxorubicin—ovarian cancer	3.05e-05	0.00034	CcSEcCtD
Lamivudine—Dyspnoea—Doxorubicin—ovarian cancer	3.03e-05	0.000337	CcSEcCtD
Lamivudine—Feeling abnormal—Epirubicin—ovarian cancer	3.03e-05	0.000337	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—ovarian cancer	3.02e-05	0.000336	CcSEcCtD
Lamivudine—Gastrointestinal pain—Epirubicin—ovarian cancer	3.01e-05	0.000334	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—ovarian cancer	2.99e-05	0.000333	CcSEcCtD
Lamivudine—Decreased appetite—Doxorubicin—ovarian cancer	2.96e-05	0.000329	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	2.94e-05	0.000327	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—ovarian cancer	2.93e-05	0.000326	CcSEcCtD
Lamivudine—Urticaria—Epirubicin—ovarian cancer	2.92e-05	0.000325	CcSEcCtD
Lamivudine—Pain—Doxorubicin—ovarian cancer	2.91e-05	0.000323	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—ovarian cancer	2.91e-05	0.000323	CcSEcCtD
Lamivudine—Abdominal pain—Epirubicin—ovarian cancer	2.91e-05	0.000323	CcSEcCtD
Lamivudine—Body temperature increased—Epirubicin—ovarian cancer	2.91e-05	0.000323	CcSEcCtD
Lamivudine—Feeling abnormal—Doxorubicin—ovarian cancer	2.8e-05	0.000312	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.78e-05	0.000309	CcSEcCtD
Lamivudine—Hypersensitivity—Epirubicin—ovarian cancer	2.71e-05	0.000301	CcSEcCtD
Lamivudine—Urticaria—Doxorubicin—ovarian cancer	2.7e-05	0.0003	CcSEcCtD
Lamivudine—Body temperature increased—Doxorubicin—ovarian cancer	2.69e-05	0.000299	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—ovarian cancer	2.69e-05	0.000299	CcSEcCtD
Lamivudine—Asthenia—Epirubicin—ovarian cancer	2.64e-05	0.000293	CcSEcCtD
Lamivudine—Pruritus—Epirubicin—ovarian cancer	2.6e-05	0.000289	CcSEcCtD
Lamivudine—Diarrhoea—Epirubicin—ovarian cancer	2.52e-05	0.00028	CcSEcCtD
Lamivudine—Hypersensitivity—Doxorubicin—ovarian cancer	2.51e-05	0.000279	CcSEcCtD
Lamivudine—Asthenia—Doxorubicin—ovarian cancer	2.44e-05	0.000271	CcSEcCtD
Lamivudine—Dizziness—Epirubicin—ovarian cancer	2.43e-05	0.00027	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—ovarian cancer	2.41e-05	0.000268	CcSEcCtD
Lamivudine—Vomiting—Epirubicin—ovarian cancer	2.34e-05	0.00026	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—ovarian cancer	2.33e-05	0.000259	CcSEcCtD
Lamivudine—Rash—Epirubicin—ovarian cancer	2.32e-05	0.000258	CcSEcCtD
Lamivudine—Dermatitis—Epirubicin—ovarian cancer	2.32e-05	0.000257	CcSEcCtD
Lamivudine—Headache—Epirubicin—ovarian cancer	2.3e-05	0.000256	CcSEcCtD
Lamivudine—Dizziness—Doxorubicin—ovarian cancer	2.25e-05	0.00025	CcSEcCtD
Lamivudine—Nausea—Epirubicin—ovarian cancer	2.18e-05	0.000243	CcSEcCtD
Lamivudine—Vomiting—Doxorubicin—ovarian cancer	2.16e-05	0.00024	CcSEcCtD
Lamivudine—Rash—Doxorubicin—ovarian cancer	2.14e-05	0.000238	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—ovarian cancer	2.14e-05	0.000238	CcSEcCtD
Lamivudine—Headache—Doxorubicin—ovarian cancer	2.13e-05	0.000237	CcSEcCtD
Lamivudine—Nausea—Doxorubicin—ovarian cancer	2.02e-05	0.000225	CcSEcCtD
Lamivudine—ABCC4—Hemostasis—CAV1—ovarian cancer	1.39e-05	0.000242	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.39e-05	0.000242	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PIK3CB—ovarian cancer	1.39e-05	0.000242	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PIK3CG—ovarian cancer	1.37e-05	0.000239	CbGpPWpGaD
Lamivudine—PGK1—Disease—MAPK1—ovarian cancer	1.37e-05	0.000238	CbGpPWpGaD
Lamivudine—PGK1—Disease—EGFR—ovarian cancer	1.37e-05	0.000238	CbGpPWpGaD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.35e-05	0.000235	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—YAP1—ovarian cancer	1.35e-05	0.000235	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.34e-05	0.000234	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CYTB—ovarian cancer	1.34e-05	0.000234	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	1.32e-05	0.000231	CbGpPWpGaD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.32e-05	0.000231	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	1.32e-05	0.00023	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PTEN—ovarian cancer	1.31e-05	0.000228	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HDAC6—ovarian cancer	1.31e-05	0.000228	CbGpPWpGaD
Lamivudine—DCK—Metabolism—ABCB1—ovarian cancer	1.3e-05	0.000227	CbGpPWpGaD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.3e-05	0.000227	CbGpPWpGaD
Lamivudine—PGK1—Disease—KRAS—ovarian cancer	1.29e-05	0.000225	CbGpPWpGaD
Lamivudine—ABCC2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.28e-05	0.000223	CbGpPWpGaD
Lamivudine—DCK—Metabolism—TYMS—ovarian cancer	1.28e-05	0.000223	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—BRIP1—ovarian cancer	1.27e-05	0.000222	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PPP1CC—ovarian cancer	1.27e-05	0.000222	CbGpPWpGaD
Lamivudine—ABCC1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.27e-05	0.000221	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PIK3CG—ovarian cancer	1.26e-05	0.000221	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—BRIP1—ovarian cancer	1.26e-05	0.00022	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PPP1CC—ovarian cancer	1.26e-05	0.00022	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—YAP1—ovarian cancer	1.24e-05	0.000216	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.22e-05	0.000214	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NME2—ovarian cancer	1.22e-05	0.000213	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PIK3CA—ovarian cancer	1.22e-05	0.000212	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PIK3CA—ovarian cancer	1.22e-05	0.000212	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PIK3CA—ovarian cancer	1.22e-05	0.000212	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PIK3CD—ovarian cancer	1.2e-05	0.00021	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTEN—ovarian cancer	1.2e-05	0.000209	CbGpPWpGaD
Lamivudine—PGK1—Disease—PIK3CA—ovarian cancer	1.19e-05	0.000207	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.18e-05	0.000206	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—BRIP1—ovarian cancer	1.17e-05	0.000205	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PPP1CC—ovarian cancer	1.17e-05	0.000205	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	1.16e-05	0.000202	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.15e-05	0.0002	CbGpPWpGaD
Lamivudine—ABCC1—Disease—XIAP—ovarian cancer	1.13e-05	0.000198	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.11e-05	0.000194	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PIK3CD—ovarian cancer	1.11e-05	0.000194	CbGpPWpGaD
Lamivudine—ABCC1—Disease—SMARCA4—ovarian cancer	1.11e-05	0.000193	CbGpPWpGaD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.1e-05	0.000192	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—FASN—ovarian cancer	1.1e-05	0.000191	CbGpPWpGaD
Lamivudine—PGK1—Disease—HRAS—ovarian cancer	1.1e-05	0.000191	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	1.09e-05	0.000191	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—SLC5A5—ovarian cancer	1.08e-05	0.000188	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EREG—ovarian cancer	1.08e-05	0.000188	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.08e-05	0.000188	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.05e-05	0.000184	CbGpPWpGaD
Lamivudine—PGK1—Disease—IL6—ovarian cancer	1.05e-05	0.000183	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PIK3CB—ovarian cancer	1.05e-05	0.000183	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—SLC2A1—ovarian cancer	1.04e-05	0.000182	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	1.04e-05	0.000181	CbGpPWpGaD
Lamivudine—DCK—Metabolism—CAV1—ovarian cancer	1.03e-05	0.00018	CbGpPWpGaD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.03e-05	0.000179	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—FASN—ovarian cancer	1.01e-05	0.000176	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CYP1B1—ovarian cancer	1e-05	0.000174	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—AKT1—ovarian cancer	9.95e-06	0.000174	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—AKT1—ovarian cancer	9.95e-06	0.000174	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—AKT1—ovarian cancer	9.95e-06	0.000174	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PIK3CA—ovarian cancer	9.93e-06	0.000173	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—SLC5A5—ovarian cancer	9.92e-06	0.000173	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	9.76e-06	0.00017	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—YAP1—ovarian cancer	9.7e-06	0.000169	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PIK3CB—ovarian cancer	9.69e-06	0.000169	CbGpPWpGaD
Lamivudine—PGK1—Disease—AKT1—ovarian cancer	9.69e-06	0.000169	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	9.68e-06	0.000169	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.6e-06	0.000167	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—SLC2A1—ovarian cancer	9.58e-06	0.000167	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FASN—ovarian cancer	9.44e-06	0.000165	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PARP1—ovarian cancer	9.4e-06	0.000164	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PIK3CG—ovarian cancer	9.4e-06	0.000164	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.38e-06	0.000164	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	9.36e-06	0.000163	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PIK3CA—ovarian cancer	9.23e-06	0.000161	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CYP1B1—ovarian cancer	9.19e-06	0.00016	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTEN—ovarian cancer	9.07e-06	0.000158	CbGpPWpGaD
Lamivudine—ABCC1—Disease—SLC2A1—ovarian cancer	8.97e-06	0.000156	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IL2—ovarian cancer	8.9e-06	0.000155	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PPP2R1A—ovarian cancer	8.87e-06	0.000155	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—YAP1—ovarian cancer	8.53e-06	0.000149	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	8.49e-06	0.000148	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—YAP1—ovarian cancer	8.44e-06	0.000147	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PIK3CA—ovarian cancer	8.44e-06	0.000147	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.44e-06	0.000147	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.34e-06	0.000145	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PIK3CD—ovarian cancer	8.26e-06	0.000144	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ABCB1—ovarian cancer	8.23e-06	0.000144	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PPP2R1A—ovarian cancer	8.15e-06	0.000142	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—AKT1—ovarian cancer	8.11e-06	0.000141	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.11e-06	0.000141	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—TYMS—ovarian cancer	8.08e-06	0.000141	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—MAPK1—ovarian cancer	7.96e-06	0.000139	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—FASN—ovarian cancer	7.9e-06	0.000138	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.9e-06	0.000138	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—YAP1—ovarian cancer	7.87e-06	0.000137	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CYTB—ovarian cancer	7.87e-06	0.000137	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	7.86e-06	0.000137	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—SLC5A5—ovarian cancer	7.78e-06	0.000136	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—HRAS—ovarian cancer	7.77e-06	0.000135	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	7.71e-06	0.000134	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.63e-06	0.000133	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PPP2R1A—ovarian cancer	7.62e-06	0.000133	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ABCB1—ovarian cancer	7.57e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—VEGFA—ovarian cancer	7.56e-06	0.000132	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—AKT1—ovarian cancer	7.54e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—SLC2A1—ovarian cancer	7.51e-06	0.000131	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.5e-06	0.000131	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—NRAS—ovarian cancer	7.47e-06	0.00013	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—TYMS—ovarian cancer	7.43e-06	0.00013	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	7.43e-06	0.00013	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—MAPK1—ovarian cancer	7.42e-06	0.000129	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.35e-06	0.000128	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.24e-06	0.000126	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PIK3CB—ovarian cancer	7.2e-06	0.000126	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CYP1B1—ovarian cancer	7.2e-06	0.000126	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—MAPK3—ovarian cancer	7.16e-06	0.000125	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—FASN—ovarian cancer	6.96e-06	0.000121	CbGpPWpGaD
Lamivudine—NME2—Metabolism—AKT1—ovarian cancer	6.9e-06	0.00012	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—FASN—ovarian cancer	6.88e-06	0.00012	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—BRIP1—ovarian cancer	6.88e-06	0.00012	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PPP1CC—ovarian cancer	6.88e-06	0.00012	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—SLC5A5—ovarian cancer	6.84e-06	0.000119	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—MAPK1—ovarian cancer	6.81e-06	0.000119	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—SLC5A5—ovarian cancer	6.77e-06	0.000118	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—SLC2A1—ovarian cancer	6.61e-06	0.000115	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—SLC2A1—ovarian cancer	6.54e-06	0.000114	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.54e-06	0.000114	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CAV1—ovarian cancer	6.51e-06	0.000114	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—KRAS—ovarian cancer	6.43e-06	0.000112	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—FASN—ovarian cancer	6.42e-06	0.000112	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PIK3CA—ovarian cancer	6.4e-06	0.000112	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—HRAS—ovarian cancer	6.39e-06	0.000111	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PPP2R1A—ovarian cancer	6.39e-06	0.000111	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.35e-06	0.000111	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CYP1B1—ovarian cancer	6.34e-06	0.00011	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—SLC5A5—ovarian cancer	6.31e-06	0.00011	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CYP1B1—ovarian cancer	6.27e-06	0.000109	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTEN—ovarian cancer	6.22e-06	0.000108	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.19e-06	0.000108	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—SLC2A1—ovarian cancer	6.1e-06	0.000106	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TERT—ovarian cancer	6.06e-06	0.000106	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	6.02e-06	0.000105	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CAV1—ovarian cancer	5.99e-06	0.000104	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—HRAS—ovarian cancer	5.95e-06	0.000104	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PIK3CG—ovarian cancer	5.93e-06	0.000103	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ABCB1—ovarian cancer	5.93e-06	0.000103	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PIK3CA—ovarian cancer	5.91e-06	0.000103	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.89e-06	0.000103	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.88e-06	0.000103	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CYP1B1—ovarian cancer	5.84e-06	0.000102	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—TYMS—ovarian cancer	5.82e-06	0.000102	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.72e-06	9.97e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—ovarian cancer	5.72e-06	9.97e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PPP2R1A—ovarian cancer	5.62e-06	9.8e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CAV1—ovarian cancer	5.6e-06	9.77e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	5.56e-06	9.7e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.56e-06	9.69e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—HRAS—ovarian cancer	5.47e-06	9.53e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PIK3CG—ovarian cancer	5.45e-06	9.51e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—IL6ST—ovarian cancer	5.31e-06	9.26e-05	CbGpPWpGaD
Lamivudine—NME1—Metabolism—AKT1—ovarian cancer	5.23e-06	9.12e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ABCB1—ovarian cancer	5.22e-06	9.1e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PIK3CD—ovarian cancer	5.22e-06	9.1e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	5.18e-06	9.04e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ABCB1—ovarian cancer	5.16e-06	9e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—TYMS—ovarian cancer	5.12e-06	8.93e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	5.11e-06	8.9e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—APC—ovarian cancer	5.1e-06	8.9e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—TYMS—ovarian cancer	5.07e-06	8.84e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.94e-06	8.61e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—AKT1—ovarian cancer	4.83e-06	8.42e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ABCB1—ovarian cancer	4.81e-06	8.39e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PIK3CD—ovarian cancer	4.79e-06	8.36e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—TYMS—ovarian cancer	4.73e-06	8.24e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CAV1—ovarian cancer	4.69e-06	8.18e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—YAP1—ovarian cancer	4.61e-06	8.04e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PIK3CB—ovarian cancer	4.55e-06	7.93e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PIK3CD—ovarian cancer	4.49e-06	7.82e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.48e-06	7.82e-05	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PIK3CA—ovarian cancer	4.39e-06	7.65e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PIK3CG—ovarian cancer	4.27e-06	7.45e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PIK3CB—ovarian cancer	4.18e-06	7.29e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.17e-06	7.27e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CAV1—ovarian cancer	4.13e-06	7.2e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CAV1—ovarian cancer	4.09e-06	7.12e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ERBB2—ovarian cancer	3.96e-06	6.91e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTEN—ovarian cancer	3.93e-06	6.85e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PIK3CB—ovarian cancer	3.91e-06	6.82e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MTOR—ovarian cancer	3.91e-06	6.82e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CAV1—ovarian cancer	3.81e-06	6.64e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PIK3CG—ovarian cancer	3.76e-06	6.56e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—FASN—ovarian cancer	3.76e-06	6.56e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PIK3CD—ovarian cancer	3.76e-06	6.55e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PIK3CG—ovarian cancer	3.72e-06	6.49e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—SLC5A5—ovarian cancer	3.7e-06	6.45e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CDKN1B—ovarian cancer	3.67e-06	6.4e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTEN—ovarian cancer	3.61e-06	6.3e-05	CbGpPWpGaD
Lamivudine—DCK—Metabolism—AKT1—ovarian cancer	3.59e-06	6.25e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—SLC2A1—ovarian cancer	3.57e-06	6.23e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PIK3CG—ovarian cancer	3.47e-06	6.05e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CTNNB1—ovarian cancer	3.47e-06	6.04e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CYP1B1—ovarian cancer	3.43e-06	5.97e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTEN—ovarian cancer	3.38e-06	5.89e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PIK3CD—ovarian cancer	3.31e-06	5.76e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PIK3CB—ovarian cancer	3.27e-06	5.71e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PIK3CD—ovarian cancer	3.27e-06	5.7e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PIK3CD—ovarian cancer	3.05e-06	5.32e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	3.04e-06	5.3e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—STAT3—ovarian cancer	3.02e-06	5.27e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NRAS—ovarian cancer	3.01e-06	5.26e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MAPK3—ovarian cancer	2.89e-06	5.03e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.88e-06	5.02e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PIK3CB—ovarian cancer	2.85e-06	4.97e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTEN—ovarian cancer	2.83e-06	4.93e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MYC—ovarian cancer	2.81e-06	4.9e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PIK3CA—ovarian cancer	2.77e-06	4.83e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—TYMS—ovarian cancer	2.77e-06	4.83e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MAPK1—ovarian cancer	2.75e-06	4.79e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EGFR—ovarian cancer	2.75e-06	4.79e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PIK3CB—ovarian cancer	2.66e-06	4.63e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KRAS—ovarian cancer	2.59e-06	4.52e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PIK3CA—ovarian cancer	2.55e-06	4.44e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTEN—ovarian cancer	2.49e-06	4.34e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTEN—ovarian cancer	2.46e-06	4.3e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PIK3CA—ovarian cancer	2.38e-06	4.16e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTEN—ovarian cancer	2.3e-06	4e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—AKT1—ovarian cancer	2.26e-06	3.95e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CAV1—ovarian cancer	2.23e-06	3.89e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HRAS—ovarian cancer	2.21e-06	3.85e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—IL6—ovarian cancer	2.11e-06	3.68e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—AKT1—ovarian cancer	2.08e-06	3.63e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.03e-06	3.55e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PIK3CA—ovarian cancer	2e-06	3.48e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—AKT1—ovarian cancer	1.95e-06	3.4e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.79e-06	3.12e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.76e-06	3.06e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	1.74e-06	3.03e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—AKT1—ovarian cancer	1.63e-06	2.84e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	1.62e-06	2.83e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.56e-06	2.72e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—AKT1—ovarian cancer	1.43e-06	2.5e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—AKT1—ovarian cancer	1.42e-06	2.48e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTEN—ovarian cancer	1.35e-06	2.35e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—AKT1—ovarian cancer	1.32e-06	2.31e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PIK3CA—ovarian cancer	9.5e-07	1.66e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—AKT1—ovarian cancer	7.76e-07	1.35e-05	CbGpPWpGaD
